Form 10-Q · Quarterly report
IDEX Corporation 10-Q, filed Oct 28, 2026
- Filed
- CIK
- 0000832101
- Accession no.
- 0000832101-26-000029
Summary
IDEX Corporation reported third-quarter 2026 net sales of $951.7 million, up 8% from a year earlier on both a reported and organic basis, with diluted EPS of $1.95 (up 15%) and adjusted diluted EPS of $2.33 (up 15%). The company said the U.S. Supreme Court's February 2026 decision invalidating broad-based IEEPA tariffs let it collect substantially all anticipated refunds of previously paid tariffs, and that it absorbed the tariffs imposed in 2025 and early 2026 without material impact.
Key points
- IDEX returned $74.6 million of share repurchases and $54.0 million of dividends to shareholders in the quarter.
- Organic sales growth was driven by higher volumes, primarily in the Health & Science Technologies segment, on AI-driven demand for data center power and semiconductor markets plus strength in space and defense.
- Health & Science Technologies net sales rose 14% to $433.5 million with adjusted EBITDA margin of 28.8%; Fluid & Metering Technologies net sales rose 3% to $327.9 million.
- The company recorded $3.4 million of restructuring expenses and asset impairments in the quarter, mainly severance tied to employee reductions including the anticipated closure of a Health & Science Technologies facility.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview IDEX is an applied solutions provider specializing in the manufacturing of health and science technologies, fluid and metering technologies, and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business, as well as by the relationship of the U.S. Dollar to other currencies. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.